233 related articles for article (PubMed ID: 29929749)
1. Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer.
Dai HY; Ma Y; Da Z; Hou XM
Pathol Res Pract; 2018 Aug; 214(8):1130-1135. PubMed ID: 29929749
[TBL] [Abstract][Full Text] [Related]
2. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
3. TRIM66 hastens the malignant progression of non-small cell lung cancer via modulating MMP9-mediated TGF-β/SMAD pathway.
Chen W; Zhang Y; Fang Z; Qi W; Xu Y
Cytokine; 2022 May; 153():155831. PubMed ID: 35301175
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of TRIM66 inhibits cell proliferation, migration and invasion in colorectal cancer through JAK2/STAT3 pathway.
He T; Cui J; Wu Y; Sun X; Chen N
Life Sci; 2019 Oct; 235():116799. PubMed ID: 31472144
[TBL] [Abstract][Full Text] [Related]
5. TRIM66 Promotes Malignant Progression of Non-Small-Cell Lung Cancer Cells via Targeting MMP9.
Xu Y; Yang Q; Fang Z; Tan X; Zhang M; Chen W
Comput Math Methods Med; 2022; 2022():6058720. PubMed ID: 35912155
[TBL] [Abstract][Full Text] [Related]
6. TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome.
Chen Y; Guo Y; Yang H; Shi G; Xu G; Shi J; Yin N; Chen D
Oncotarget; 2015 Sep; 6(27):23708-19. PubMed ID: 26247633
[TBL] [Abstract][Full Text] [Related]
7. TRIM66 expression in non-small cell lung cancer: A new predictor of prognosis.
Ma Y; Dai HY; Zhang F; Zhao D
Cancer Biomark; 2017 Sep; 20(3):309-315. PubMed ID: 28946563
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway.
Zheng CH; Chen XM; Zhang FB; Zhao C; Tu SS
Cell Biol Int; 2018 Sep; 42(10):1386-1394. PubMed ID: 29972256
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.
Lu W; Zhang H; Niu Y; Wu Y; Sun W; Li H; Kong J; Ding K; Shen HM; Wu H; Xia D; Wu Y
Mol Cancer; 2017 Jul; 16(1):118. PubMed ID: 28697764
[TBL] [Abstract][Full Text] [Related]
10. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 knockdown suppresses vasculogenic mimicry of non-small cell lung cancer by modulating ZEB1-triggered EMT.
Li W; Wu J; Jia Q; Shi Y; Li F; Zhang L; Shi F; Wang X; Wu S
BMC Cancer; 2024 May; 24(1):633. PubMed ID: 38783271
[TBL] [Abstract][Full Text] [Related]
12. Effects of Linc00460 on cell migration and invasion through regulating epithelial-mesenchymal transition (EMT) in non-small cell lung cancer.
Yue QY; Zhang Y
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):1003-1010. PubMed ID: 29509248
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of TRIM66 in MDA-MB-468 triple negative breast cancer cell line suppresses proliferation and promotes apoptosis through EGFR signaling.
Zhang H; Zheng Y; Zhang Y
Pol J Pathol; 2021; 72(2):160-166. PubMed ID: 34706523
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
15. FOXO1 Inhibits Tumor Cell Migration via Regulating Cell Surface Morphology in Non-Small Cell Lung Cancer Cells.
Gao Z; Liu R; Ye N; Liu C; Li X; Guo X; Zhang Z; Li X; Yao Y; Jiang X
Cell Physiol Biochem; 2018; 48(1):138-148. PubMed ID: 30001537
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of SATB2 is critical for induction of epithelial-to-mesenchymal transition and invasion of NSCLC cells.
Kucuksayan H; Ozes ON; Akca H
Lung Cancer; 2016 Aug; 98():122-129. PubMed ID: 27393518
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition by regulating TGFβ1/Smad2 in human non-small cell lung cancer.
Zhang JX; Zhai JF; Yang XT; Wang J
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(18):3793-3801. PubMed ID: 27735039
[TBL] [Abstract][Full Text] [Related]
18. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
19. The crosstalk between p38 and Akt signaling pathways orchestrates EMT by regulating SATB2 expression in NSCLC cells.
Kucuksayan H; Akca H
Tumour Biol; 2017 Sep; 39(9):1010428317706212. PubMed ID: 28937318
[TBL] [Abstract][Full Text] [Related]
20. Gli promotes tumor progression through regulating epithelial-mesenchymal transition in non-small-cell lung cancer.
Jiang L; Huang J; Hu Y; Lu P; Luo Q; Wang L
J Cardiothorac Surg; 2020 Jan; 15(1):18. PubMed ID: 31931858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
